Better Therapeutics, Inc. (BTTX)
BTTX moved a median of -1.80% 30 minutes after news, and -2.86% by the close. How BTTX actually reacts to news — the realized, point-in-time move the market made, measured across 80 labeled events over the last three years with zero look-ahead.
BTTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.27% | 39% | 77 |
| 30-min | -1.80% | 36% | 77 |
| 60-min | -1.39% | 40% | 77 |
| to close | -2.86% | 37% | 79 |
| Middle 50% of BTTX reactions | -6.82% to +2.49% |
|---|---|
| Median reaction (30-min) | -1.80% |
| Measured reactions | 80 |
Half of all Better Therapeutics, Inc. news events land between -6.82% and +2.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BTTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BTTX's baseline. Nothing else.
Recent BTTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Better Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | +28.20% | +46.86% | |
| Form EFFECT Better Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +17.65% | |
| Form POS AM Better Therapeutics, | SEC filing · Form POS | SEC EDGAR | -9.09% | -9.09% | |
| Form S-8 POS Better Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -9.09% | -9.09% | |
| Form 8-K Better Therapeutics, For: Mar 15 | SEC filing · Form 8-K | SEC EDGAR | +4.17% | +42.88% | |
| Form 8-K Better Therapeutics, For: Mar 14 | SEC filing · Form 8-K | SEC EDGAR | +17.74% | -34.60% | |
| Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq | Press release | Business Wire | -6.16% | -30.42% | |
| Form 8-K Better Therapeutics, For: Mar 14 | SEC filing · Form 8-K | SEC EDGAR | -6.16% | -30.42% | |
| Form 8-K Better Therapeutics, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -2.23% | -8.64% | |
| Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers | Press release | Business Wire | -1.50% | -10.00% | |
| Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) | Press release | Business Wire | -2.15% | +4.36% | |
| Form 8-K Better Therapeutics, For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | +4.36% | |
| Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | Accesswire | -0.06% | +11.82% | |
| Form RW Better Therapeutics, | SEC filing · Form RW | SEC EDGAR | -0.06% | +11.82% | |
| Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease | Press release | Business Wire | -13.99% | -28.32% | |
| Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment | Press release | Business Wire | -5.89% | -2.78% | |
| Form S-1/A Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -4.95% | -12.50% | |
| Form D Better Therapeutics, | SEC filing · Form D | SEC EDGAR | -1.35% | -11.07% | |
| Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone | Press release | Business Wire | -5.81% | -3.84% | |
| Form 8-K Better Therapeutics, For: Jan 03 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | +15.00% | |
| Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States | Press release | Business Wire | — | — | |
| Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease | Press release | Business Wire | -7.88% | -10.00% | |
| Form EFFECT Better Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.27% | +1.92% | |
| Form S-1/A Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -0.11% | -0.67% | |
| Form S-1/A Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -8.79% | -3.66% | |
| Form 8-K Better Therapeutics, For: Dec 14 | SEC filing · Form 8-K | SEC EDGAR | -2.53% | -9.40% | |
| Form S-1/A Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -2.53% | -9.40% | |
| Form 8-K Better Therapeutics, For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | +7.03% | +17.33% | |
| Form S-1 Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +7.03% | +17.33% | |
| Form 8-K Better Therapeutics, For: Nov 27 | SEC filing · Form 8-K | SEC EDGAR | +5.50% | +3.17% | |
| Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions | Press release | Business Wire | +2.22% | +15.00% | |
| Form 8-K Better Therapeutics, For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +5.26% | +7.79% | |
| Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award | Press release | Business Wire | -1.96% | -1.59% | |
| Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates | Press release | Business Wire | -7.35% | -9.94% | |
| Form 10-Q Better Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.35% | -9.94% | |
| Form 8-K Better Therapeutics, For: Nov 09 | SEC filing · Form 8-K | SEC EDGAR | -7.35% | -9.94% | |
| Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023 | Press release | Business Wire | +1.06% | -0.88% | |
| Form 8-K Better Therapeutics, For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | +4.32% | +4.02% | |
| Form S-1/A Better Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -4.32% | -7.95% | |
| Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference | Press release | Business Wire | -3.27% | +5.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BTTX section they belong to.
Where else BTTX is measured.
BTTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Better Therapeutics, Inc.'s median reaction calculated?
Every labeled BTTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 80 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of BTTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BTTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.